GC
PRQR icon

Guggenheim Capital’s ProQR Therapeutics PRQR Stock Holding History

Guggenheim Capital’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$74.3K Buy
39,954
+12,310
+45% +$20.3K ﹤0.01% 1697
2026
Q1 		$44.8K Buy
27,644
+10,420
+60% +$17.1K ﹤0.01% 1593
2025
Q4 		$34.8K Buy
+17,224
New +$40.3K ﹤0.01% 1739

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Guggenheim Capital's PRQR Position: Q2 2026 in Review

Guggenheim Capital increased its ProQR Therapeutics (PRQR) stake by 45% in Q2 2026, buying an estimated $20.3K and bringing the position to 39,954 shares worth $74.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1697.

Guggenheim Capital first reported a position in PRQR in Q4 2025 and has held it in 3 quarters since. 70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

  • Guggenheim Capital held 39,954 shares of ProQR Therapeutics worth $74.3K as of Q2 2026.
  • Guggenheim Capital bought 12,310 ProQR Therapeutics shares in Q2 2026, an estimated $20.3K.
  • ProQR Therapeutics made up ﹤0.01% of Guggenheim Capital's portfolio in Q2 2026, its #1697 holding.
  • Guggenheim Capital first reported a position in ProQR Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.